Skip to content

Evaluation of the Clinical Performance of Reinforced Glass Ionomer Restorations

Evaluation of the Clinical Performance of Reinforced Glass Ionomer Restorations

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04288791
Enrollment
20
Registered
2020-02-28
Start date
2018-06-01
Completion date
2019-02-01
Last updated
2020-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Caries

Brief summary

This study is conducted to evaluate the clinical performance of class I reinforced glass ionomer restorations (Zirconomer Improved and Equia Forte Fil)

Interventions

Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.

Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 47 Years
Healthy volunteers
Yes

Inclusion criteria

* Normal occlusal relation with normal dentition. * Absence of pain from the tooth to be restored. * Absence of any active periodontal and pulpal diseases from the tooth to be restored. * Medium-sized (buccolingually and mesio-distally) occlusal carious lesions extending into dentin.

Exclusion criteria

* Patients with a history of tooth sensitivity. * Patients with bruxism. * Defective restorations adjacent or opposing to the tooth. * Abutment teeth used for fixed or removable prosthesis. * Patients who refused to sign the consent form. * Inability to return to recall appointments

Design outcomes

Primary

MeasureTime frameDescription
Clinical Performance of the restoration6 monthsSuccess Rate

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026